Stem Cell Clinic

Stem Cell Therapy is a Must Try Method for Permanent Relief from Pain, Says Integrated Medical Center of Corona – Press Release – Digital Journal

By Stem Cell Medical Center

Corona, CA - December 19, 2019 - Chronic pain can be debilitating, and it drastically reduces the quality of life. Until recently, patients had to go through the dread of operations, surgeries, pain killers and downtime, but no longer. At the Integrated Medical Center of Corona, stem cell therapy today allows doing away with the very source of pain in an office setting, without having to go under the knife.

It could be called soup therapy for muscles, joints and tendons. The soup here comprises a powerful and healing concoction of stem cells, ozone, and plasma rich platelets, which is directly injected into the affected region. These ingredients replace the pain causing cells and naturally replace them with healthy, regenerated, identical cells.

Many of the patients at the Integrated Medical Center of Corona vouch for the efficacy and ease with which they got rid of chronic painful conditions in the neck, joints, hips or shoulders. With no risky surgery or harmful drugs involved, a non-invasive, quick procedure in an office setting is all it took to bring back the old lifestyle!

For years, patients have been forced to fly to other countries around the world to experience the healing miracle of Regenerative Medicine. Now it is available right here in your local community, with complete professionalism. We treat our patients as family. It is that simple, says Dr. Anthony Pirritano, owner of IMCC.

With regenerative therapy, chronic pain can be quickly and completely eliminated. A single visit brings about great relief. There is no downtime in bed or use of crutches or slings. Stem cell therapy allows patients to live a completely pain free life.

The Clinic is led by Dr. Anthony Pirritano, who has been practicing for over 20 years helping patients live a pain-free life with proven cellular therapies. With the most advanced techniques and high levels of service, the Clinic offers a serene and relaxing ambience to receive the most advanced pain relieving therapies.

Integrated Medical Center of Corona offers everyone a free consultation on how stem cell and regenerative therapy can help get rid of painful conditions.

About

Integrated Medical is a full-service, comprehensive wellness center dedicated to specialized, non-invasive, and rehabilitative medicine. Passionate about excellence in patient care, Integrated Medical Center provides traditional and holistic treatment for a wide variety of ailments, including most musculoskeletal injuries (whiplash, neck, low back pain, headaches, knee pain, pain/numbness in the arms or legs, etc.), weight gain, hormonal issues (low testosterone), pain management, and many other conditions.

For more information, please visit: http://www.integratedmedicalcenterofcorona.com

Media ContactCompany Name: Integrated Medical Center of CoronaContact Person: Jason Kimes, Marketing ManagerEmail: Send EmailPhone: (800) 595-2447Address:2250 S. Main Street, Suite # 203 City: CoronaState: CACountry: United StatesWebsite: https://www.integratedmedicalcenterofcorona.com/

See original here:
Stem Cell Therapy is a Must Try Method for Permanent Relief from Pain, Says Integrated Medical Center of Corona - Press Release - Digital Journal

Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center – BioSpace

By Stem Cell Medical Center

NEW YORK, Dec. 19, 2019 /PRNewswire/ --The New York Genome Center (NYGC) announced today that Hackensack Meridian Health and the Georgetown Lombardi Comprehensive Cancer Center have become the two newest institutional associate members of the NYGC.

Hackensack Meridian Health is New Jersey's largest health care network. Its Center for Discovery and Innovation (CDI) and John Theurer Cancer Center at Hackensack University Medical Center, a member of the Georgetown Lombardi consortium, are key components of the network's strategy to develop and employ the latest genomic medicine for patients. Georgetown Lombardi Comprehensive Cancer Center is Washington, D.C.'s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and NCI-approved consortium.

"We are excited to have these leading institutions with distinguished physician-scientists and researchers join the New York Genome Center community," said Tom Maniatis, PhD, Evnin Family Scientific Director and Chief Executive Officer, NYGC. "We look forward to working with their teams to further our collaborative efforts to accelerate genomics research."

"The Center for Discovery and Innovation is a key element of our mission to transform health care and lead toward the future," said Robert C. Garrett, FACHE, Chief Executive Officer, Hackensack Meridian Health. "The John Theurer Cancer Center continues to provide the most advanced care currently available. Through our new partnerships at the New York Genome Center, patients in New Jersey and beyond will benefit from the latest technologies for personalized medicine."

"The New York Genome Center is a unique and critical nexus for research collaboration in the genomics community, and the Georgetown Lombardi Comprehensive Cancer Center consortium is pleased to join NYGC's member institutions to partner in cancer genomics research," said Louis M. Weiner, MD, Director, Georgetown Lombardi Comprehensive Cancer Center and the MedStar Georgetown Cancer Institute.

The new members are joining the NYGC through two separate partnerships with distinct collaborative research objectives. The first partnership, to be led by Hackensack Meridian Health's CDI, is focused on exploring the genetics underlying the risk factors for behavioral disorders and identifying genetic markers that help physicians predict and manage these disorders more effectively. The second partnership is focused on cancer genomics and led by Georgetown Lombardi Comprehensive Cancer Center, which includes investigators from Georgetown University Medical Center, along with the Hackensack Meridian Health's John Theurer Cancer Center and CDI. This partnership will seek to use advanced genetic analyses to better understand risk factors for emergence of certain aggressive cancers, such as pediatric brain tumors; why certain cancers fail to respond to immunotherapy; and identify genetic markers or cellular factors that can improve patient outcomes.

"This is a leap forward for the CDI and its mission to translate scientific innovation from the laboratory to treatments for patients," said David S. Perlin, PhD, Chief Scientific Officer and Senior Vice President of the CDI. "Our world-class scientists will benefit from connecting and collaborating with colleagues at leading New York-region institutions."

Given their areas of research focus, Hackensack Meridian Healthand Georgetown Lombardi Comprehensive Cancer Center will be participants in the Genome Center Cancer Group (GCCG), NYGC's founding scientific working group, which is composed of clinicians and cancer researchers from NYGC's member institutions. With the addition of these new members, the GCCG now includes seven NCI-designated Comprehensive Cancer Centers. The GCCG is led by Nobel Laureate Harold Varmus, MD, Senior Associate Core Member, NYGC, and Lewis Thomas University Professor of Medicine, Weill Cornell Medicine, and Charles Sawyers, MD, Chair, Human Oncology and Pathogenesis Program, Marie-Jose and Henry R. Kravis Chair, Memorial Sloan Kettering Cancer Center, and Affiliate Member, NYGC. The GCCG recently launched Polyethnic-1000, a project to study cancer in ethnically diverse, underserved patient populations, and is also spearheading the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers. In addition, the NYGC is utilizing the application of novel statistical approaches and population-level analyses to major cohorts in cancer genomics.

Researchers from Hackensack Meridian Health's CDI also are expected to engage in NYGC's Neuropsychiatric Disease Scientific Working Group. It is led by Dr. Maniatis; Michael Zody, PhD, Scientific Director, Computational Biology; and Thomas Lehner, PhD, MPH, formerly of the National Institute of Mental Health of the National Institutes of Health, who arrives to the NYGC in January in the new position of Scientific Director of Neuropsychiatric Disease Genomics. Reporting to Dr. Maniatis, Dr. Lehner will lead the expansion of the NYGC's innovative, large-scale whole genome autism research into other neuropsychiatric disease areas, including schizophrenia and bipolar disorder.

Georgetown Lombardi Comprehensive Cancer Center and Hackensack Meridian Health join NYGC's institutional associate members, which include American Museum of Natural History, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute, and its 12 institutional founding members: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine.

About the New York Genome Center The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. Leveraging our strengths in whole genome sequencing, genomic analysis, and development of new genomic tools, the NYGC serves as a nexus for collaboration in disease-focused genomic research for the New York medical and academic communities and beyond.

NYGC harnesses the expertise and builds on the combined strengths of our faculty, staff scientists, member institutions, scientific working groups, affiliate members, and industry partners to advance genomic discovery. Central to our scientific mission is an outstanding faculty who lead independent research labs based at the NYGC, and hold joint tenure-track appointments with one of our member institutions.

Institutional founding members of the NYGC are: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine. Institutional associate members are: American Museum of Natural History, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian Health, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute.

For more information on the NYGC, please visit:http://www.nygenome.org.

Media Contact:Karen Zipern, Director, Communications, NYGCkzipern@nygenome.orgo: 646-977-7065c: 917-415-8134

View original content:http://www.prnewswire.com/news-releases/hackensack-meridian-health-and-georgetown-lombardi-comprehensive-cancer-center-become-associate-members-of-the-new-york-genome-center-300977742.html

SOURCE New York Genome Center

See the original post here:
Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center - BioSpace

Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc – OrthoSpineNews

By Stem Cell Medical Center

NEWPORT NEWS, Va.,Dec. 18, 2019/PRNewswire/ Orthopaedic and Spine Center announced Dr.Jeffrey Carlson, Orthopaedic Spine Surgeon, became the first surgeon in Central andEastern Virginiaarea to implant the M6-Cartificial cervical disc. The outpatient surgery was performed on a 53 year old female at Bon Secours/Mercy Health Mary Immaculate Hospital inNewport News, VirginiaonNovember 20, 2019.

The patient reported symptoms of severe neck pain which radiated to both shoulders after a motor vehicle accident. After she failed to respond to conservative treatment, an MRI was ordered revealing severe spinal stenosis and spinal cord abutment at level C3-4 caused by a herniated disc. In consultation with Dr. Carlson, the patient made the decision to have cervical disc arthroplasty, using the Orthofix M6-C artificial cervical disc.

Ive been waiting for the right patient with the appropriate diagnosis to employ the M6-C disc, said Carlson. The technology used in this procedure facilitates a speedy recovery with minimal limitations and a great outcome, so that my patient can get back to her active life. She just had her two week post-surgical follow-up appointment her recovery is going very well and she feels much relief from the severe pain she once experienced.

The M6-C disc received U.S. Food and Drug Approval in February 2019.It was designed to closely mimic the anatomic structure of a natural disc as well as provide an effective alternative to a spinal fusion. By allowing the spine to move naturally, the M6-C artificial disc potentially minimizes stress to adjacent discs and other vertebral structures.

AboutJeffrey R. Carlson, M.D.Dr.Jeffrey Carlsonhas been a part of Orthopaedic & Spine Center since 1999 and serves as the President and Managing Partner. He is a board-certified, fellowship-trained orthopaedic surgeon who focuses on the treatment of injuries and disorders of the spine.

About Orthopaedic & Spine CenterOrthopaedic & Spine Center (OSC) is staffed by outstanding medical professionals who strive to provide the very best orthopaedic and interventional pain management care available anywhere. Our Center includes a comfortable, state-of-the-art medical facility, pleasant and well-trained personnel, physicians trained in the most advanced orthopaedic treatments, interventional pain management procedures, regenerative medicine, using stem cell and platelet therapies and a dedication to old-fashioned patient care.

SOURCE Orthopaedic & Spine Center

osc-ortho.com

Read this article:
Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc - OrthoSpineNews

Experts and Attitude Help Grandfather Face Primary Central Nervous System Lymphoma – Dana-Farber Cancer Institute

By Stem Cell Medical Center

Steve Kelley is the quintessential glass half-full guy. Still, he realizes his reaction to learning he had an extremely rare cancer known as central nervous system (CNS) lymphoma may seem unusual.

Afew weeks after his June 2018 diagnosis, Kelley, then 64, gathered his familyand friends together. He didnt want to focus negatively on the uncertainoutcome or his upcoming treatment at Dana-Farber/Brigham and Womens CancerCenter (DF/BWCC).

Hejust wanted to celebrate the present.

Ive always seen myself as someone who deals with whatever life puts in front of me, says Kelley of the pre-treatment party he organized at a bowling alley near his home in Sharon, Mass. I wanted everybody to know I felt the same way now, even with cancer. I was celebrating the challenge ahead.

Sincethen, through intensive chemotherapy, followed by an autologous stem celltransplant in November 2018, and then several months re-strengthening hisimmune system, the father and grandfather of four has kept up this positivity.

Whileits true he lost his hair, fingernails, and dealt with other serious sideeffects during treatment, Kelley explains, things have greatly improved sincethen. Forced to go without his favorite activities of swimming and mountain bikingfor a while, he is now feeling strong enough to think about triathlons. Heseven handling snow plowing and other duties associated with the real estatemanagement and roofing businesses he founded at age 19, and still leads today withthe help of sons Phil and Dave.

Andif he must be among those living with primary CNS lymphoma, Kelley says, he couldnthave picked a better time or place.

The Central Nervous System Lymphoma Center, established at DF/BWCC in December 2017, was the first facility in the world dedicated to providing comprehensive care and research for patients with this rare cancer. The center offers advanced treatment options including surgical biopsy, chemotherapy, radiation therapy, immunotherapy, and targeted therapy, as well as placement for qualified patients on clinical trials.

Itell you, Im one lucky son of a gun, says Kelley.

Itis Kelleys upbeat attitude, he believes, that led him to initially miss the warningsigns of his CNS lymphoma. Two areas impacted by the cancer are eyesight and orientation;although he had been having trouble with both for several months, he says helearned to subconsciously compensate.

Asstrange as it sounds, I would tilt my head left or right to see, says Kelley.Things didnt get really bad until one day when I was driving six miles to myhouse on a route I had known for years. There wasnt a lot of traffic, but Ikept seeing lines across my eyes, and was so disoriented it took me three hoursto get home. When I told my wife, she insisted we go to the nearest emergencyroom.

There an MRI revealed a mass in Kelleys head, and he was immediately sent to DF/BWCC for more tests. He then had what he calls another stroke of good fortune, in the form of oncologist Lakshmi Nayak, MD, director of the Central Nervous System Lymphoma Center. Right away, Nayak and physician assistant Alexandra Torres, PA-C, put Kelley at ease with their knowledge and warmth.

Dr. Nayak analyzed my condition and synthesized a treatment plan that brought me back from the kind of a cliff that I was holding onto, Kelley says. She was terrific.

Similarly,Nayak says, Kelleys approach to that plan was helpful.

Hewas certainly a perfect candidate for undergoing an autologous transplantbecause of his age and fitness, says Nayak, but importantly, his attitudethroughout the arduous process was amazing.

Kelley, who meets regularly with Nayak and her team for checkups, has not yet had a cancer recurrence. Recently he marked a year since his stem cell transplant with another celebration Thanksgiving with his family and in March he plans to meet with a specialist at DF/BWCC to work on improving the cognitive skills impacted by his diagnosis.

Meanwhile, with the ongoing support of his incredible wife, family, and close friends, Kelley is keeping his spirits up and forging ahead. In addition to running his company, he is enjoying a 20-year secondary career as a Cambridge College professor. Among the courses he teaches are leadership, conflict management, and effective listening, all of which he says have been indispensable guideposts in his recovery.

Its funny I was already working on writing a book about how people can help themselves through tough times, and now Im reworking it to include my cancer journey, Kelley says. One of the things I like to tell people is that maturity is the ability to make the best of any situation.

I hope to be proof of that.

Read this article:
Experts and Attitude Help Grandfather Face Primary Central Nervous System Lymphoma - Dana-Farber Cancer Institute

Stem Cell Research & Therapy | Home page

By Stell Cell Research

"Stem cells have enormous potential for alleviating suffering for many diseases which currently have no effective therapy. The field has progressed to the clinic and it is important that this pathway is underpinned by excellent science and rigorous standards of clinical research. The journal provides an important avenue of publication in translational aspects of stem cell therapy spanning preclinical studies, clinical research and commercialization."

Timothy O'Brien,Editor-in-Chief,Stem Cell Research & Therapy

"The study of stem cells is one of the most exciting areas of contemporary biomedical research. We believe that Stem Cell Research & Therapy will act as a highly active forum for both basic and translational research into stem cell biology and therapies. Specifically, by developing this forum for cutting edge research, we hope that Stem Cell Research & Therapy will play a significant role in bringing together the critical information to synergize stem cell science with stem cell therapies."

Rocky S Tuan,Editor-in-Chief,Stem Cell Research & Therapy

Read more here:
Stem Cell Research & Therapy | Home page

Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio – Business…

By Stell Cell Research

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global allogeneic stem cells market and the market is poised to grow by USD 1.24 billion during 2020-2024 at a CAGR of over 12% during the forecast period. Request Free Sample Pages

Read the 131-page research report with TOC on "Allogeneic Stem Cells Market Analysis Report by geography (Asia, Europe, North America, and ROW), by application (regenerative therapy and drug discovery and development), and segment forecasts, 2020-2024".

https://www.technavio.com/report/allogeneic-stem-cells-market-industry-analysis

The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allogeneic Stem Cells Market Companies:

Biosolution Co. Ltd.

Biosolution Co. Ltd. is headquartered in South Korea (Republic of Korea) and operates the business under its Unified business segment. The company offers an allogeneic keratinocyte spread medication, Keraheal-Allo, that promotes skin regeneration.

Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative therapeutics for the treatment of various diseases. The company provides a mesenchymal stem cell product, Cymerus, which is used to treat graft-versus-host disease.

JCR Pharmaceuticals Co. Ltd.

JCR Pharmaceuticals Co. Ltd. is headquartered in Japan and operates under two business segments, namely Pharmaceuticals, and Medical Devices and Laboratory Equipment. The company offers a regenerative medical product, TEMCELL HS Injection, which uses human mesenchymal stem cells for the treatment of acute graft-versus-host disease.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. is headquartered in the US and offers products through its Unified business segment. The company provides OpRegen, which is currently being tested in a Phase I/IIa clinical trial. This product is intended for the treatment of dry AMD.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd. is headquartered in South Korea (Republic of Korea) and offers products through its Unified business segment. The company provides an allogeneic umbilical cord blood-derived mesenchymal stem cell drug, CARTISTEM, which is used for the treatment of knee cartilage defects.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Allogeneic Stem Cells Application Outlook (Revenue, USD Million, 2020-2024)

Allogeneic Stem Cells Regional Outlook (Revenue, USD Million, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original:
Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Business...

3D Cell Culture Market: Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation – Global Forecast to 2024 – ResearchAndMarkets.com -…

By Stell Cell Research

DUBLIN--(BUSINESS WIRE)--The "3D Cell Culture Market by Product (Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharmaceutical, Biotech, Cosmetics), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7%

The growth in this market is primarily driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to limit market growth during the forecast period.

The microfluidics-based 3D cell cultures segment is projected to grow at the highest CAGR during the forecast period.

Based on product, the 3D cell culture market is segmented into scaffold-based, scaffold-free, microfluidics-based, and magnetic & bioprinted 3D cell cultures. The microfluidics-based segment is expected to register the highest CAGR during the forecast period. Funding initiatives from various government and private investors are among the key factors driving the growth of this market.

Cancer and stem cell research segment accounted for the largest share of the 3D cell culture market in 2018.

On the basis of application, the 3D cell culture market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. Cancer & stem cell research segment accounted for the largest share of the market in 2018. The increasing prevalence of cancer and significant funding initiatives for cancer research from the government as well as the private sector are some of the major factors driving the growth of this application segment.

Europe to witness high growth during the forecast period.

Based on the region, the 3D cell culture market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). The European market is expected to grow at the highest CAGR owing to the growth of the pharmaceutical and biotechnology industry, increasing incidence of cancer, growing number of venture capital investments, strategic expansion of market players in the region, recent commercialization of microfluidic-based products, increasing presence of major market players, and the large number of research activities in the region.

Market Dynamics

Market Drivers

Restraints

Opportunities

Challenges

Company Profiles

Other Key Players

For more information about this report visit https://www.researchandmarkets.com/r/aj5kod

See more here:
3D Cell Culture Market: Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation - Global Forecast to 2024 - ResearchAndMarkets.com -...

Functional "Mini-liver" Created By 3D Bioprinting – Technology Networks

By Stell Cell Research

Using human blood cells, Brazilian researchers have succeeded in obtaining hepatic organoids (mini-livers) that perform all of the livers typical functions, such as producing vital proteins, storing vitamins, and secreting bile, among many others. The innovation permits the production of hepatic tissue in the laboratory in only 90 days and may in the future become an alternative to organ transplantation.

The study was conducted at the Human Genome and Stem Cell Research Center (HUG-CELL). Hosted by the University of So Paulo (USP), HUG-CELL is one of the Research, Innovation and Dissemination Centers (RIDCs) funded by FAPESP.

This study combined bioengineering techniques, such as cell reprogramming and the cultivation of pluripotent stem cells, with 3D bioprinting. Thanks to this strategy, the tissue produced by the bioprinter maintained hepatic functions for longer than reported by other groups in previous studies.

More stages have yet to be achieved until we obtain a complete organ, but were on the right track to highly promising results. In the very near future, instead of waiting for an organ transplant, it may be possible to take cells from the patient and reprogram them to make a new liver in the laboratory. Another important advantage is zero probability of rejection, given that the cells come from the patient, said Mayana Zatz,director of HUG-CELL and last author of the article published in Biofabrication.

The innovative part of the study resided in how the cells were included in the bioink used to produce tissue in the 3D printer. Instead of printing individualized cells, we developed a method of grouping them before printing. These clumps of cells, or spheroids, are what constitute the tissue and maintain its functionality much longer, said Ernesto Goulart, a postdoctoral fellow in USPs Institute of Biosciences and first author of the article.

The researchers thereby avoided a problem faced by most human tissue bioprinting techniques, namely, the gradual loss of contact among cells and hence loss of tissue functionality.

Spheroid formation in this study already occurred in the differentiation process, when pluripotent cells were transformed into hepatic tissue cells (hepatocytes, vascular cells, and mesenchymal cells). We started the differentiation process with the cells already grouped together. They were cultured in agitation, and groups formed spontaneously, Goulart told Agncia FAPESP.

A liver in 90 days

According to the researchers, the complete process from collection of the patients blood to functional tissue production takes approximately 90 days and can be divided into three stages: differentiation, printing, and maturation.

Initially, the blood cells are reprogrammed to regress to a stage of pluripotency characteristic of stem cells, becoming induced pluripotent stem cells (iPSCs). Japanese scientist Shinya Yamanaka was awarded the 2012 Nobel Prize for Medicine for developing this technique.

The next stage consists of inducing differentiation into liver cells. The spheroids are then mixed with bioink, a hydrogel-like fluid, and printed out. The resulting structures mature in culture for 18 days.

The printing process entails the deposition of spheroids along three axes, which is necessary for the material to gain volume and give the tissue proper support, Goulart said. The gel-like bioink is crosslinked to make the structures more rigid so that they can be manipulated and even sutured.

Most of the available methods for printing live tissue use immersion and cell dispersion in a hydrogel to recapitulate the microenvironment and ensure tissue functionality. However, experiments have shown that loss of cell contact and functionality tends to occur when dispersion is performed cell by cell.

Its a somewhat traumatic process for the cells, which need time to get used to the environment and acquire functionality, Goulart said. At this stage, they arent tissue yet because theyre dispersed, but as shown by our study, they already have the capacity to clear the blood of toxins and to produce and secrete albumin [a protein produced only by the liver], for example.

In this study, researchers developed mini-livers using blood cells from three volunteers as raw material and compared markers relating to functionality, such as the maintenance of cell contact and protein production and release. Our spheroids worked much better than those obtained from single-cell dispersion. As expected, during maturation, the markers of hepatic function were not reduced, Goulart said.

Although the study was limited to producing miniature livers, the technique can be used in the future to produce complete organs suitable for transplantation, according to Goulart. We did it on a small scale, but with investment and interest, it can easily be scaled up, he said.Reference:Goulart, E., de Caires-Junior, L. C., Telles-Silva, K. A., Araujo, B. H. S., Rocco, S. A., Sforca, M., Zatz, M. (2019). 3D bioprinting of liver spheroids derived from human induced pluripotent stem cells sustain liver function and viability in vitro. Biofabrication, 12(1), 015010. https://doi.org/10.1088/1758-5090/ab4a30

This article has been republished from the following materialsoriginally published byFAPESP Agencyaccording toCreative Commons license CC-BY-NC-ND. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post here:
Functional "Mini-liver" Created By 3D Bioprinting - Technology Networks

Scientists hope MND cure is a step closer after stem cell breakthrough discovery – The National

By Stell Cell Research

SCIENTISTS hope a cure for motor neurone disease (MND) is a step closer after a research breakthrough identified cells key to the degenerative condition.

There is currently no known cure for MND, which causes signals from motor neurone nerve cells in the brain and spinal cord needed to control movement to gradually stop reaching the muscles.

Notable people who have lived with MND include Scottish rugby star Doddie Weir and Stephen Hawking.

Researchers used stem cell technology to identify a type of cell that can cause motor neurones to fail.

Using stem cells from patient skin samples, they found glial cells, which normally support neurones in the brain and spinal cord, become damaging to motor neurones in the patients with the condition.

By testing different combinations of glial cells and motor neurones grown together in the lab, researchers found glial cells from MND patients can cause motor neurones in healthy people to stop producing the electrical signals needed to control muscles.

READ MORE:BBCSports Personality of the Year award to honour Doddie Weir

Gareth Miles, a professor of neuroscience at the University of St Andrews, helped lead the joint project with the University of Edinburgh.

Miles said: We are very excited by these new findings, which clearly point the finger at glial cells as key players in this devastating disease.

Interestingly, the negative influence of glial cells seems to prevent motor neurones from fulfilling their normal roles, even before the motor neurones show signs of dying.

We hope that this new information highlights targets for the development of much-needed treatments and ultimately a cure for MND.

The joint research was published in the scientific journal Glia.

View original post here:
Scientists hope MND cure is a step closer after stem cell breakthrough discovery - The National

Stem Cell Banking Market: Adopts Innovation to Stay Competitive Forecast – Market Research Sheets

By Stell Cell Research

Global Stem Cell Banking, Market Size, Status and Forecast 2018-2026 offers a primary overview of the Stem Cell Banking, industry covering Definition, Classification, Industry Value, Price, Cost and Gross Profit, Share via Region, New Challenge Feasibility Evaluation, Analysis and Guidelines on New mission Investment. Stem Cell Banking, Market report presents in-intensity insight of Company Profile, Capacity, Product Specifications, Production Value, Sales, Revenue, Price, Gross Margin, Market Size and Market Shares for topmost prime key vendors (Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.). In the end, there are 4 key segments covered in this Stem Cell Banking, market report: competitor segment, product type segment, end use/application segment and geography segment.

Target Audience of Stem Cell Banking, Market: Suppliers, Channel Partners, Production Companies, Market Consultants, Marketing Authorities, Research Institutions, Subject Matter Experts, Financial Institutions, Government Authorities.

To Get the Concise Free Sample PDF of the Stem Cell Banking, Market Report, Along With the TOC, Statistics, and Tables Please Visit

Stem Cell Banking, Market Summary: This report includes the estimation of market size for value (million US$) and volume (K sqm). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Stem Cell Banking, market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Based on Classifications, each type is studied as Sales, Stem Cell Banking, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. each type, including:

Stem Cell Banking, Market: Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

The Middle East and Africa (GCC Countries and Egypt.)

Stem Cell Banking, Market Capacity, Production, Revenue, Consumption, Export and Import (2018-2026)

Stem Cell Banking, Market Capacity, Production and Growth

Production, Consumption, Export and Import

Revenue and Growth of Market

Stem Cell Banking, Market Forecast (2018-2026)

Stem Cell Banking, Market by Capacity, Production, Revenue Forecast

Production Forecast by Type and Price Forecast

Consumption Forecast by Application

Production, Import, Export and Consumption Forecast

Stem Cell Banking, Market Production, Consumption, Import and Export Forecast by Regions (Provinces)

For Better Understanding Go With This Free Sample Report

ABOUT USCOMPANY OVERVIEW

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market.

Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module. This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

This post was originally published on Market Research Sheets

More:
Stem Cell Banking Market: Adopts Innovation to Stay Competitive Forecast - Market Research Sheets

→←